News Release

Factor to boost MSCs & collagen II activity in intervertebral disc degeneration identified

Peer-Reviewed Publication

Mary Ann Liebert, Inc./Genetic Engineering News

Tissue Engineering, Part A

image: Tissue Engineering brings together scientific and medical experts in the fields of biomedical engineering, material science, molecular and cellular biology, and genetic engineering. view more 

Credit: Mary Ann Liebert, Inc., publishers

New Rochelle, NY, September 4, 2018--A new study has demonstrated the tissue regenerative potential of a chemoattractant delivery system that can draw mesenchymal stem cells (MSCs) to the site of intervertebral disc (IVD) degeneration. The study, carried out in a cow model of IVD degeneration, not only showed the recruitment of regenerative cells, but also reported increased collagen production, as described in an article published in , peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Click here to read the article free on the Tissue Engineering website until October 4, 2018.

Raquel Madeira Gonçalves, PhD, Universidade do Porto, Portugal and a team of researchers from Universidade do Porto and the AO Research Institute Davos, Switzerland, described the hyaluronan based-chemoattractant delivery system they developed in the article entitled "Stromal Cell Derived Factor-1-Mediated Migration of Mesenchymal Stem Cells Enhances Collagen Type II Expression in Intervertebral Disc." In the presence of the system, which contained stromal cell derived factor-1 (SDF-1), migration of MSCs to the degenerative site was enhanced. In addition, the researchers measured higher levels of collagen type II and of pro-catabolic factors produced by the MSCs that would contribute to enhanced remodeling of the extracellular matrix.

"This study exemplifies the impact of drug delivery on enhancing a specific cellular activity and thus reverting a tissue degenerative process," says Tissue Engineering Co-Editor-in-Chief Antonios G. Mikos, PhD, Louis Calder Professor at Rice University, Houston, TX.

###

About the Journal

Tissue Engineering, Part A is an authoritative peer-reviewed journal published monthly online and in print in three parts: Part A, the flagship journal published 24 times per year; Part B: Reviews, published bimonthly, and Part C: Methods, published 12 times per year. Led by Co-Editors-in-Chief Antonios G. Mikos, PhD, Louis Calder Professor at Rice University, Houston, TX, and John P. Fisher, PhD, Fischell Family Distinguished Professor & Department Chair, and Director of the NIH Center for Engineering Complex Tissues at the University of Maryland, the Journal brings together scientific and medical experts in the fields of biomedical engineering, material science, molecular and cellular biology, and genetic engineering. Leadership of Tissue Engineering Parts B (Reviews) and Part C (Methods) is provided by Katja Schenke-Layland, PhD, Eberhard Karls University, Tübingen and John A. Jansen, DDS, PhD, Radboud University, respectively. Tissue Engineering is the official journal of the Tissue Engineering & Regenerative Medicine International Society (TERMIS). Complete tables of content and a sample issue may be viewed on the Tissue Engineering website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Stem Cells and Development, Human Gene Therapy, and Advances in Wound Care. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.